Skip Navigation
Photo of Douglas E. Williams, Ph.D.

Douglas E. Williams, Ph.D., President, Chief Executive Officer

Douglas E. Williams, Ph.D., is Codiak’s President and CEO. He previously served as Biogen’s Executive Vice President, Research and Development from January 2011 to July 2015.

Dr. Williams joined Biogen from ZymoGenetics, where he was CEO and member of the Board of Directors. ZymoGenetics was acquired by Bristol Myers Squibb during his time as CEO for $985 million. Previously, he held leadership positions within the biotechnology industry, including Chief Scientific Officer and Executive Vice President of Research and Development at Seattle Genetics Inc., and Senior Vice President and Washington Site Leader at Amgen Inc.

Dr. Williams also served in a series of scientific and senior leadership positions over a decade at Immunex Corp., including Executive Vice President and Chief Technology Officer, Senior Vice President of Discovery Research and Vice President of Research and Development.

Prior to joining Immunex, Dr. Williams served on the faculty of the Indiana University School of Medicine and the Department of Laboratory Medicine at the Roswell Park Memorial Institute in Buffalo, New York. Dr. Williams has served on numerous boards of directors for companies in the biotechnology industry and is currently a member of the Board of Directors of Ovid Therapeutics, Chairman of the Board of AC Immune, and is a Director for private companies Cygnal Therapeutics and Xenikos.